Annick Desjardins
Professor of Neurosurgery · Duke University Hospital
Credentials: · ·
History
Present- Present
- Present
- 2003–2005
- 1998–2003
Sherbrooke University Hospital Centre
- 1994–1998
Research
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
Journal of Clinical Oncology · 2007 · 1,096 citations
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
Clinical Cancer Research · 2007 · 830 citations
Recurrent Glioblastoma Treated with Recombinant Poliovirus
New England Journal of Medicine · 2018 · First of 18 authors · 670 citations
100 papers
74 papers
- JV
74 papers
50 papers
48 papers
44 papers
42 papers
- DB
37 papers
Grants
- 2014–2025
- 2018–2024
Experimental Therapy for Brain Tumors
National Cancer Institute · P01
Project lead · $1.6M · Duke University
Clinical trials
- 2025–2030
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
Principal investigator · Recruiting · Phase 1
Darell Bigner
- 2023–2025
Monocyte Antigen Carrier Cells for Newly Diagnosed GBM
Principal investigator · Withdrawn · Phase 1
Michael Gunn
- 2021–2028
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
Principal investigator · Recruiting · Phase 1
Darell Bigner
- 2020–2027
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
Principal investigator · Active not recruiting · Phase 2
Annick Desjardins, MD